Honeywell International Inc vs Zoetis Inc — how do they compare? Honeywell International Inc trades at $230.22 (market cap $72.93B), while Zoetis Inc trades at $72.54 (market cap $31.14B). The key difference: Honeywell International Inc is far larger — about 2.3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| HON | ZTS | |
|---|---|---|
Market Cap | $72.93B | $31.14B |
Sector | Industrials | Health |
52-Week High | $248.79 | $156.76 |
52-Week Low | $188.14 | $71.91 |
Enterprise Value | $97.73B | $38.70B |
Dividend Yield | 1.22% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $242.93, down 1.32% on the day, with a bullish technical signal and strong fundamentals including a P/E of 8.85 and net income margin of 21.58%. Recent corporate actions include a 2:1 reverse stock split and consistent dividend payments. The stock shows robust earnings beats in recent quarters, though Q3 2026 results are pending.
The outlook is positive with a consensus price target of $320.54, indicating significant upside. Risks include recent growth guidance disappointments and competitive pressures in industrial automation. Analyst sentiment is predominantly buy-rated, supporting a favorable investment case amid ongoing portfolio simplification.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →